6869 Stock Overview
Engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 6869 from our risk checks.
Sysmex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,713.50 |
| 52 Week High | JP¥3,480.00 |
| 52 Week Low | JP¥2,236.00 |
| Beta | 0.54 |
| 1 Month Change | 10.73% |
| 3 Month Change | 1.16% |
| 1 Year Change | -13.03% |
| 3 Year Change | -24.45% |
| 5 Year Change | 5.39% |
| Change since IPO | 2,613.50% |
Recent News & Updates
Results: Sysmex Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
May 12
These 4 Measures Indicate That Sysmex (TSE:6869) Is Using Debt Reasonably Well
Apr 27Shareholder Returns
| 6869 | JP Medical Equipment | JP Market | |
|---|---|---|---|
| 7D | 0.7% | 1.4% | 0.8% |
| 1Y | -13.0% | 9.9% | 24.8% |
Return vs Industry: 6869 underperformed the JP Medical Equipment industry which returned 9.9% over the past year.
Return vs Market: 6869 underperformed the JP Market which returned 24.8% over the past year.
Price Volatility
| 6869 volatility | |
|---|---|
| 6869 Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 3.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 6869 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6869's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 9,500 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Sysmex Corporation Fundamentals Summary
| 6869 fundamental statistics | |
|---|---|
| Market cap | JP¥1.69t |
| Earnings (TTM) | JP¥49.64b |
| Revenue (TTM) | JP¥461.51b |
34.1x
P/E Ratio3.7x
P/S RatioIs 6869 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6869 income statement (TTM) | |
|---|---|
| Revenue | JP¥461.51b |
| Cost of Revenue | JP¥219.01b |
| Gross Profit | JP¥242.50b |
| Other Expenses | JP¥192.86b |
| Earnings | JP¥49.64b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 79.61 |
| Gross Margin | 52.54% |
| Net Profit Margin | 10.76% |
| Debt/Equity Ratio | 6.6% |
How did 6869 perform over the long term?
See historical performance and comparison